Humana Inc (HUM) Stock AnalysisHUMHumana Inc

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is a good buy right now due to its current price of $422.07, which is well below the analyst price target of $525 from Oppenheimer, suggesting a potential upside of 24%. Additionally, the company has seen a remarkable increase in its Medicare Advantage ratings, with 95% of members in plans rated four stars or higher, which could translate to an estimated $3.6 billion in additional revenue. However, the main risk is the upcoming earnings report with an EPS estimate of -1.03, indicating potential volatility.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.